Levin AS, Bilous RW, Coresh J. Chapter 1: definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19–62.


Google Scholar 

Iliescu EA, Yeates KE, Holland DC. Quality of sleep in patients with chronic kidney disease. Nephrol Dialysis Transpl. 2004;19(1):95–99.


Google Scholar 

Gopal A, Farragher J, Jassal SV, Mucsi I. Sleep disorders in CKD. Am J Kidney Dis. 2025.

Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997;20(11):1038–52.


Google Scholar 

Sohn JW. Network of hypothalamic neurons that control appetite. BMB Rep. 2015;48(4):229.


Google Scholar 

Gutstein H, Akil H. Opioid analgesics. In: Hardman J, Limbird L, Gilman A, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill;200.

Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24. https://doi.org/10.1016/j.smrv.2004.08.001.


Google Scholar 

Johns MW. A new method for measuring daytime sleepiness: the epworth sleepiness scale. Sleep. 1991;14(6):540–45.


Google Scholar 

Izci B, Ardic S, Firat H, Sahin A, Altinors M, Karacan I. Reliability and validity studies of the Turkish version of the epworth sleepiness scale. Sleep & Breathing = Schlaf & Atmung. 2008;12(2):161–68. https://doi.org/10.1007/s11325-007-0145-7.


Google Scholar 

Sanford SD, Lichstein KL, Durrence HH, Riedel BW, Taylor DJ, Bush AJ. The influence of age, gender, ethnicity, and insomnia on epworth sleepiness scores: a normative us population. Sleep Med: X. 2006;7(4):319–26.


Google Scholar 

Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulator α-MSH. Trends in Immunology. 1997;18(3):140-145.

Botte DAC. Avaliação do efeito anti-inflamatório do hormônio α estimulador de melanócito (Α MSH) em modelo experimental de lúpus. 2013. https://doi.org/10.11606/T.5.2013.tde-10122013-115118. Doctoral Thesis, Faculdade de Medicina, University of São Paulo, São Paulo.

Lee SY, Cho WY, Kim HK, Won NH. The effect of alpha-MSH on long-term histologic changes after acute ischemic kidney injury in rats. Korean J Nephrol. 2005;24(2):191–203.


Google Scholar 

Chiao H, Kohda Y, McLeroy P, Craig L, Linas S, Star RA. α-melanocyte-stimulating hormone inhibits renal injury in the absence of neutrophils. Kidney Int. 1998;54(3):765–74.


Google Scholar 

Oktar B, Alican İ. The actions of the Α-melanocyte stimulating hormone (Α-Msh) in inflammatory conditions. Marmara Med J. 2001;14(2):113–18.


Google Scholar 

Lee SY, Jo SK, Cho WY, Kim HK, Won NH. The effect of alpha-melanocyte-stimulating hormone on renal tubular cell apoptosis and tubulointerstitial fibrosis in cyclosporine a nephrotoxicity. Transplantation. 2004;78(12):1756–64.


Google Scholar 

Gong R. Leveraging melanocortin pathways to treat glomerular diseases. Adv Chronic Kidney Dis. 2014;21(2):134–51.


Google Scholar 

Chiu YL, Chuang YF, Fang KC, Liu SK, Chen HY, Yang JY, Tsai TJ. Higher systemic inflammation is associated with poorer sleep quality in stable haemodialysis patients. Nephrol Dialysis Transpl. 2009;24(1):247–51.


Google Scholar 

Korucu B, Erten YT, Yeter HH, Altinova A, Pasaoglu OT, Pasaoglu H, Sindel MS, Arinsoy ST, Yetkin I. Hypothalamic energy regulatory peptides in chronic kidney disease. Ther Apher Dial. 2019;23(5):437–43.


Google Scholar 

Amr EM, Montasser ZM, Amel FK. Inflammatory status in patients on chronic hemodialysis.2004.

Koch BC, van der Putten K, Van Someren EJ, Wielders JP, Ter Wee PM, Nagtegaal JE, Gaillard CA. Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (cream study). Nephrol, Dialysis, Transpl: Off Publ of The Eur Dialysis and Transpl Assoc – Eur Renal Assoc. 2010;25(2):513–19. https://doi.org/10.1093/ndt/gfp493.


Google Scholar 

Karasek M, Szuflet A, Chrzanowski W, Zylinska K, Swietoslawski J. Decreased melatonin nocturnal concentrations in hemodialyzed patients. Neuro Endocrinol Lett. 2005;26(6):653–56.


Google Scholar 

Elder SJ, Pisoni RL, Akizawa T, Fissell R, Andreucci VE, Fukuhara S, Saran R. Sleep quality predicts quality of life and mortality risk in haemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dialysis Transpl. 2008;23(3):998–1004.


Google Scholar 

Noda A, Nakai S, Soga T, Sugiura T, Iwayama N, Maeda K, Atarashi M, Yasuma F, Ozaki N, Yokota M, Koike Y. Factors contributing to sleep disturbance and hypnotic drug use in hemodialysis patients. Intern Med. 2006;45(22):1273–78.


Google Scholar 

Tan LH, Chen PS, Chiang HY, King E, Yeh HC, Hsiao YL, Chang DR, Chen SH, Wu MY, Kuo CC. Insomnia and poor sleep in CKD: a systematic review and meta-analysis. Kidney Med. 2022;4(5):100458.


Google Scholar 

Ahmad S, Gupta M, Gupta R, Dhyani M. Prevalence and correlates of insomnia and obstructive sleep apnea in chronic kidney disease. N Am J Med Sci. 2013;5(11):641–46.


Google Scholar 

Hui DS, Wong TY, Ko FW, Li TS, Choy DK, Wong KK, Szeto CC, Lui SF, Li PK. Prevalence of sleep disturbances in Chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis: The Off J Natl Kidney Foundation. 2000;36(4):783–88.


Google Scholar 

Nicholl DDM, Ahmed SB, Loewen AHS, Hemmelgarn BR, Sola DY, Beecroft JM, Turin TC, Hanly PJ. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest. 2012;141(6):1422–30.

Abdelwhab S, Kamel M, Noshey M. Sleep disorders in hemodialysis patients. Kidney. 2010;19:175–81.